

Electronic Acknowledgement Receipt

EFS ID:	4250078
Application Number:	10729475
International Application Number:	
Confirmation Number:	3082
Title of Invention:	Pharmacological vitreolysis
First Named Inventor/Applicant Name:	Steve Pakola
Customer Number:	23483
Filer:	Hollie L. Baker./Kristen Moussalli
Filer Authorized By:	Hollie L. Baker.
Attorney Docket Number:	113476.122U51
Receipt Date:	07-NOV-2008
Filing Date:	05-DEC-2003
Time Stamp:	17:36:30
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2739
Deposit Account	080219
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Asami_Ultrastructure.pdf	476941	no	7
			edf5d6f3c50ed7774b7135d771968c97531a67		
Warnings:					
Information:					
2	NPL Documents	Azzolini_Intrasurgical139.pdf	49836	no	2
			d8800c23e703ce1791e2607761b411023e0c7e		
Warnings:					
Information:					
3	NPL Documents	Azzolini_Intrasurgical138.pdf	362141	no	8
			6c57c7bad38916d384b7c7c6f532e8b8277a		
Warnings:					
Information:					
4	NPL Documents	Bhisitkul_Anticipation.pdf	109426	no	4
			4c58648bd15b68f00ce1340e1288a0f8c0db0ef		
Warnings:					
Information:					
5	NPL Documents	Bishop_StructuralMacromolecules.pdf	1006501	no	22
			65d8ee1af016b4704a7a6d6d28113c269a0c17		
Warnings:					
Information:					
6	NPL Documents	Chen_Enzymatic.pdf	361956	no	8
			ecd5fbd3a273ac1c95c9fe5c9619c0f3c9b027		
Warnings:					
Information:					
7	NPL Documents	Chow_SuccessfulClosure.pdf	421634	no	5
			900c141022276526953f747026a01b2c0c159		
Warnings:					
Information:					
8	NPL Documents	Collen_RevivalPlasmin.pdf	554329	no	2
			6c29001a0c850c84b64010b4097b7b037a69		

Warnings:					
Information:					
9	NPL Documents	Foos_Vitreoretinal.pdf	1285147 24f8acc941af384dc44b25b45069823d773d8f	no	8
Warnings:					
Information:					
10	NPL Documents	Gandorfer_Experimental.pdf	1000365 d4b158f7d5d86d4d3d1ec22d1591510ca25d5d11	no	7
Warnings:					
Information:					
11	NPL Documents	Gandorfer_Intrasurgical.pdf	43554 f4b7883dc648b4c7c6d7266c7b7d442018e48d	no	1
Warnings:					
Information:					
12	NPL Documents	Gonias_Macroglubin.pdf	1306208 8ec7e765d54e3d73088c9d1012d6ec7db3c67d41	no	6
Warnings:					
Information:					
13	NPL Documents	Hara_SurfaceStructure.pdf	2937725 ab25d749d0ca12d7c188c9eeb4b193b4d67d6a	no	8
Warnings:					
Information:					
14	NPL Documents	Hermel_Efficacy.pdf	397255 a59a1c787197a5a8ba23ae05b4992e5eef2b03	no	8
Warnings:					
Information:					
15	NPL Documents	Jorge_Intravitreal.pdf	1090246 c1713abce03bf501d811ba64c3674bcae635ba	no	7
Warnings:					
Information:					
16	NPL Documents	Joshi_Intracsis.pdf	678547 f38f6bf15d46d75cd41da0120d02a116997b80e	no	4
Warnings:					
Information:					
17	NPL Documents	Joshi_Posterior.pdf	806289 ba1d4b609b3a0ca6928f19a8bcb7c5d2289c2c4d	no	4

Warnings:					
Information:					
18	NPL Documents	Kohno_Immunofluorescent.pdf	1639476 e8f7c5a6e8cf38f7b57ae8f6551ef19fcd0b56ba	no	9
Warnings:					
Information:					
19	NPL Documents	Laryukhina_1977_Vestn_Oftal mol_6_77.pdf	438898 99e086d9e410e3c517a6659d1b339b2c3055a013	no	4
Warnings:					
Information:					
20	NPL Documents	Li_Posterior.pdf	307308 e762a200ffca7bf8f88ae7c2d272202ea919f8b0	no	7
Warnings:					
Information:					
21	NPL Documents	Okajima_EndothelialCell.pdf	2846195 1b6ccf73b6a1f134e85255dbb6e05de3e7f9c2b	no	9
Warnings:					
Information:					
22	NPL Documents	Proksch_Nonclinical.pdf	313749 2234188f56661cebda81b7c3f892c23f6f855fe	no	14
Warnings:					
Information:					
23	NPL Documents	Quiram_Microplasmin.pdf	541294 9b09982b21b39c3273b6c26ff8bb430595405d	no	7
Warnings:					
Information:					
24	NPL Documents	Rizzo_Autologous.pdf	161527 8a04e8554e2318b69eca5fc70204c79bb5cf9db4c	no	5
Warnings:					
Information:					
25	NPL Documents	Sakuma_Efficacy.pdf	2710514 e08439c7353d573f1336f442b5d81a912f0f081	no	8
Warnings:					
Information:					
26	NPL Documents	Sakuma_UseAutologous.pdf	293354 956b66d1a483c3841b29718c2780507d9281e	no	3

Warnings:					
Information:					
27	NPL Documents	Sebag_Retina18.pdf	258066 613aa75a9811502db8e67a3c81c1056cd157d88	no	3
Warnings:					
Information:					
28	NPL Documents	Sebag_Retina22.pdf	313431 77b7647ef9a02952e03b8ee5cd771e2a1f10a35	no	4
Warnings:					
Information:					
29	NPL Documents	Sebag_Morphology.pdf	3751939 b86d2675d80c8ee58875ac76d3d7f22b28c88	no	5
Warnings:					
Information:					
30	NPL Documents	Sebag_Pharmacologic.pdf	151211 65a81d38173e13a15605d18a74328811963c2d	no	5
Warnings:					
Information:					
31	NPL Documents	Shapiro_Activation.pdf	5793303 b8cd5574ee58cd93a70384e1889182b446c761af	no	6
Warnings:					
Information:					
32	NPL Documents	Stack_Binding.pdf	1460516 cd1709995d2d411567a1175c5cd8813c79f3db1	no	6
Warnings:					
Information:					
33	NPL Documents	Staubach_Enzyme.pdf	128290 2f1eb019d2d0764b2084d199c3ed47a15c50d8	no	9
Warnings:					
Information:					
34	NPL Documents	Takano_Intravitreal.pdf	348552 a05d4ee5370bd4702788d17d767e3b36f29100191	no	7
Warnings:					
Information:					
35	NPL Documents	Takano_PosteriorVitreous.pdf	406559 d89178c2d7ec575816cc998a303c26d0599a0b	no	5

Warnings:					
Information:					
36	NPL Documents	Trese_Enzymatic.pdf	1350955 2288424133a66d966373943edffae103ace1a2	no	6
Warnings:					
Information:					
37	NPL Documents	Wang_Safety.pdf	389292 3a1880ac93948cd65dcdb7a281a30f55612de9778	no	5
Warnings:					
Information:					
38	NPL Documents	Wang_PVD.pdf	615499 932a7a7a7988eefc321903cae9f8ae4f9718b993	no	6
Warnings:					
Information:					
39	NPL Documents	Wu_PreparationPurification.pdf	819201 c3ca9f5fd47c0ba2aef5c03fb56e528f84e	no	4
Warnings:					
Information:					
40	NPL Documents	Wu_Plasmin.pdf	734222 e083a9e3a66499f98c41f7f62088e93334816	no	7
Warnings:					
Information:					
41	NPL Documents	Wu_PediatricTraumatic.pdf	1069166 6c39d05c6abdc6a34b28106c5812f7aa5f0ecc	no	7
Warnings:					
Information:					
42	NPL Documents	Suenson_Secondary.pdf	2051535 8c8073c6593c28233c8f48ca3215701147219b	no	10
Warnings:					
Information:					
43	NPL Documents	Marder_Plasmin.pdf	1060901 012bafe78b775c36e81463778156ae81e11d861	no	7
Warnings:					
Information:					
44	NPL Documents	Kim_LongtermEffects.pdf	670411 afac9c0aa97c0bc36c3c28076422f3c0f9e0	no	6

Warnings:					
Information:					
45	NPL Documents	Goldberg_Interaction.pdf	1671172 931a95a8b6ca5b19a8854a9b3e0c2702fd4d	no	9
Warnings:					
Information:					
46	NPL Documents	Sebag_Molecular.pdf	2833039 a919fcc129082ac52401e13471a293ff15aadb8	no	22
Warnings:					
Information:					
47	NPL Documents	Moser_Extracellular.pdf	1495837 152131cc9790e1d6a6cab12be055ba0095d57a90	no	7
Warnings:					
Information:					
48	NPL Documents	Powell_Activation.pdf	1066226 c903e9814887aea7735cae606f05b1fab38d16	no	7
Warnings:					
Information:					
49		113476_122US1_IDS.pdf	404294 d49183dd01d8e078861141c60b78c2952863a	yes	8
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement Letter		1	2	
	Information Disclosure Statement (IDS) Filed (SB/08)		3	8	
Warnings:					
Information:					
50	Fee Worksheet (PTO-06)	fee-info.pdf	29992 2e5276cd375eb56753eebb5d0c50e0c5d0204	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			51014024		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.